Insider Buying: NextCure (NASDAQ:NXTC) Major Shareholder Acquires $18,676.20 in Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc bought 3,662 shares of the company’s stock in a transaction dated Friday, November 6th. The stock was bought at an average cost of $5.10 per share, with a total value of $18,676.20. Following the completion of the transaction, the insider owned 737,956 shares in the company, valued at approximately $3,763,575.60. This trade represents a 0.50% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Thursday, November 5th, Adar1 Capital Management, Llc purchased 1,024 shares of NextCure stock. The shares were bought at an average price of $5.10 per share, for a total transaction of $5,222.40.
• On Tuesday, October 27th, Adar1 Capital Management, Llc purchased 3,553 shares of NextCure stock. The shares were bought at an average price of $5.10 per share, for a total transaction of $18,120.30.
• On Monday, October 26th, Adar1 Capital Management, Llc purchased 1,672 shares of NextCure stock. The stock was bought at an average cost of $5.03 per share, with a total value of $8,410.16.
• On Friday, October 23rd, Adar1 Capital Management, Llc purchased 5,626 shares of NextCure stock. The stock was bought at an average cost of $4.83 per share, with a total value of $27,173.58.

NextCure Price Performance

Shares of NXTC opened at $5.98 on Thursday. NextCure, Inc. has a one year low of $1.55 and a one year high of $15.74. The company has a 50-day simple moving average of $6.04 and a two-hundred day simple moving average of $7.60. The firm has a market capitalization of $27.38 million, a PE ratio of -0.88 and a beta of 1.22.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.39).

Institutional Investors Weigh In On NextCure

An institutional investor recently raised its position in NextCure stock. Renaissance Technologies LLC boosted its position in shares of NextCure, Inc. (NASDAQ:NXTC) by 80.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 60,534 shares of the company’s stock after purchasing an additional 26,900 shares during the quarter. Renaissance Technologies LLC owned about 1.68% of NextCure worth $647,000 at the end of the most recent reporting period. Institutional investors own 42.65% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on NXTC shares. Wall Street Zen upgraded NextCure from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings upgraded NextCure from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Finally, HC Wainwright reiterated a “buy” rating on shares of NextCure in a report on Thursday, August 13th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $20.00.

NextCure Company Profile

NextCure, Inc. (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells. NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.